Bristol Myers Squibb Company $BMY Shares Acquired by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR boosted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 4.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 265,264 shares of the biopharmaceutical company’s stock after buying an additional 10,647 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Bristol Myers Squibb were worth $16,552,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of BMY. Primecap Management Co. CA purchased a new position in Bristol Myers Squibb during the 2nd quarter worth $1,436,115,000. Legal & General Group Plc purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $980,862,000. BlackRock Inc. raised its holdings in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the last quarter. State Street Corp raised its holdings in shares of Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after purchasing an additional 7,192,724 shares during the last quarter. Finally, Caisse de depot et placement du Quebec bought a new position in shares of Bristol Myers Squibb during the second quarter valued at about $243,646,000. 76.41% of the stock is currently owned by institutional investors.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Encouraging cancer-drug data strengthens the growth pipeline. Izalontamab brengitecan (Iza-Bren) reportedly doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer. Separate Phase 3 data indicated the drug reduced breast-cancer progression risk by as much as 38%. The results could support a future growth driver as Bristol Myers Squibb manages declines from older products. Iza-Bren lung cancer trial results
• Positive Sentiment: Valuation remains supportive. One analysis argues that BMY still trades below fair value based on expected future cash generation, despite its strong 12-month advance. Analysts also point to growth medicines and higher Eliquis guidance as potential offsets to legacy-portfolio weakness. BMY valuation analysis
• Neutral Sentiment: Third-quarter earnings are the next major catalyst. Preview coverage is focused on revenue trends, Eliquis performance, newer growth products and the pace of decline in older drugs. The market is waiting to see whether operating results support the company’s full-year EPS guidance of $6.75–$7.00. Q3 earnings preview
• Neutral Sentiment: Analyst sentiment is cautious but not bearish. Piper Sandler lowered its price target from $82 to $78 while retaining an Overweight rating, implying further upside. Zacks Research maintains a Hold rating and trimmed its Q3 2027, FY2027 and FY2028 EPS estimates only slightly, to $1.55, $6.23 and $5.21, respectively. Piper Sandler BMY target
• Negative Sentiment: Patent expirations remain the principal risk. Declining sales from key legacy medicines could pressure earnings, and estimates already imply lower profitability in later years. Investors must weigh the pipeline’s commercialization potential against this erosion. BMY bargain or value trap analysis

Insider Buying and Selling

In other news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the topic of several analyst reports. Royal Bank Of Canada restated a “sector perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 19th. William Blair reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Raymond James Financial assumed coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Wells Fargo & Company dropped their target price on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating on the stock in a research report on Tuesday, October 13th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $76.00 target price on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $65.50.

Bristol Myers Squibb Stock Up 0.0%

Shares of Bristol Myers Squibb stock opened at $61.63 on Wednesday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The stock has a fifty day moving average price of $63.09 and a 200-day moving average price of $59.85.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities research analysts expect that Bristol Myers Squibb Company will post 6.51 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.1%.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.